Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
Phase 1/2 study testing AMT-130 in Huntington's disease.
Active, not recruitingPhase 1 / Phase 2GeneticClinicalTrials.govTreatment trial
Recruiting in: Ann Arbor, Baltimore, Birmingham +9 more, United States
Sponsor: UniQure Biopharma B.V.
Preparing a short plain-English summary.